Ventripoint Diagnostics Announces Justin Leushner
as New President and Management Restructuring
Toronto, Ontario, September 19, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that Justin Leushner has been appointed the President of Ventripoint.
“We are delighted Justin has taken on the role of President. Having worked in a variety of senior management roles, he has a deep understanding of the medical diagnostics industry and the markets in which we operate. He is a strong, dynamic leader with an impressive track record fostering innovation, ensuring growth and delivering results” commented Dr. George Adams, Ventripoint’s CEO.
Mr. Leushner has had an extensive and diverse business career in the life sciences and biotechnology industries. He developed a national molecular diagnostics program for MDS Inc., Canada’s largest life science’s company, and served as a business analyst and portfolio advisor to the Canadian Medical Discoveries Fund. In 2004, Justin co-founded Sernova Corp., currently traded on the Toronto Stock Exchange. In addition, he developed an Islet Transplant Program for the London Health Sciences Centre and served as Director for Health Care Restructuring. His many years in hospital and laboratory settings have provided him with a comprehensive understanding of the procurement and processes involved in adopting innovations within a patient provider setting. Justin is active in the development and commercialization of medical technologies, having founded and financed multiple biotech companies. He has served on boards and in an advisory capacity for investors, institutions and industry. An MBA graduate of the University of Western Ontario’s Ivey School of Business, Justin also holds a B.Sc. in Cell Physiology/Genetics from the University of British Columbia and numerous technical designations in Forensic Science and Molecular Biology.
“Ventripoint is a driving force in the cardiac diagnostics markets and I am honored to lead our mission to the next level of commercial success. I look forward to working with the team as we continue to transform and bring innovative products to hospitals worldwide,” notes Justin Leushner.
Desmond Hirson, as the Chief Technology Officer, will be responsible for the commercialization of the next-generation VMS+ system and will lead the efforts as the Company embarks on new technological advancements in medical imaging.
As part of the restructuring, Dr. Alvira Macanovic is now Senior Director, Operations, Regulatory Affairs & Quality Assurance and Jessica Naman is the Director of Marketing.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release